Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges

References

• Rojas-Lopez M, Monterio R, Pizza M, Desvaux M, Rosini R. Intestinal pathogenic Escherichia coli: insights for vaccine development. Front Microbiol. 2018;9:440. doi:10.3389/fmicb.2018.00440.
   PubMed Web of Science ®Google Scholar
• Poolman JT, Wacker M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis. 2016;213(1):6–25. doi:10.1093/infdis/jiv429.
   PubMed Web of Science ®Google Scholar
• Dale AP, Woodford N. Extra-intestinal pathogenic Escherichia coli (ExPEC): disease, carriage and clones. J Infect. 2015;71(6):615–626. doi:10.1016/j.jinf.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 2003;5(5):449–456. doi:10.1016/S1286-4579(03)00049-2.
   PubMed Web of Science ®Google Scholar
• Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17(2):227–241. doi:10.1016/S0891-5520(03)00005-9.
   PubMed Web of Science ®Google Scholar
• Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host–pathogen interactions and new treatment strategies. Nat Rev Microbiol. 2020;18(4):211–226. doi:10.1038/s41579-020-0324-0.
   PubMed Web of Science ®Google Scholar
• Al-Qassimi MA, Al Amad M, Anam L, Almoayed K, Al-Dar A, Ezzadeen F. Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020. BMC Infect Dis. 2022;22(1):414. doi:10.1186/s12879-022-07397-0.
   PubMed Web of Science ®Google Scholar
• Billips BK, Yaggie RE, Cashy JP, Schaeffer AJ, Klumpp DJ. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis. 2009;200(2):263–272. doi:10.1086/599839.
   PubMed Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine. 2007;25(19):3859–3870. doi:10.1016/j.vaccine.2007.01.100.
   PubMed Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, MacDonald U, Cope JJ. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Vaccine. 2009;27(3):388–395. doi:10.1016/j.vaccine.2008.10.082.
   PubMed Web of Science ®Google Scholar
• Magistro G, Stief CG. Vaccine development for urinary tract infections: where do we stand? European Urology Focus. 2019;5(1):39–41. doi:10.1016/j.euf.2018.07.034.
   PubMedGoogle Scholar
• Hachen HJ. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol. 1990;143(4):759–762. discussion 762-763. doi:10.1016/s0022-5347(17)40084-x.
   PubMed Web of Science ®Google Scholar
• Frey C, Obolensky W, Wyss H. Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int. 1986;41(6):444–446. doi:10.1159/000281253.
   PubMed Web of Science ®Google Scholar
• Wade DT, Cooper J, Peckham N, Belci M. Immunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial. Clin Rehabil. 2020;34(12):1458–1464. doi:10.1177/0269215520946065.
   PubMed Web of Science ®Google Scholar
• Kim KS, Kim JY, Jeong IG, Paick J-S, Son H, Lim DJ, Shim HB, Park WH, Jung HC, Choo M-S. et al. A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis. J Korean Med Sci. 2010;25(3):435–439. doi:10.3346/jkms.2010.25.3.435.
   PubMed Web of Science ®Google Scholar
• Bauer HW, Alloussi S, Egger G, Blümlein H-M, Cozma G, Schulman CC. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47(4):542–548. discussion 548. doi:10.1016/j.eururo.2004.12.009.
   PubMed Web of Science ®Google Scholar
• Magasi P, Pánovics J, Illés A, Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol. 1994;26(2):137–140. doi:10.1159/000475363.
   PubMed Web of Science ®Google Scholar
• Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German urinary tract infection study group. Br J Urol. 1990;65(1):6–9. doi:10.1111/j.1464-410x.1990.tb14649.x.
   PubMedGoogle Scholar
• Schulman CC, Corbusier A, Michiels H, Taenzer HJ. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol. 1993;150(3):917–921. doi:10.1016/s0022-5347(17)35648-3.
   PubMed Web of Science ®Google Scholar
• Krebs J, Stoyanov J, Wöllner J, Valido E, Pannek J. Immunomodulation for primary prevention of urinary tract infections in patients with spinal cord injury during primary rehabilitation: protocol for a randomized placebo-controlled pilot trial (UROVAXOM-pilot). Trials. 2021;22(1):677. doi:10.1186/s13063-021-05630-w.
   PubMed Web of Science ®Google Scholar
• Krebs J, Fleischli S, Stoyanov J, Pannek J. Effects of oral immunomodulation therapy on urinary tract infections in individuals with chronic spinal cord injury-A retrospective cohort study. Neurourol Urodyn. 2019;38(1):346–352. doi:10.1002/nau.23859.
   PubMed Web of Science ®Google Scholar
• Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007;177(4):1349–1353. doi:10.1016/j.juro.2006.11.093.
   PubMed Web of Science ®Google Scholar
• Grischke EM, Rüttgers H. Treatment of bacterial infections of the female urinary tract by immunization of the patients. Urol Int. 1987;42(5):338–341. doi:10.1159/000281988.
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WH, Dahmer LA, Balish E. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J Urol. 1994;152(6 Part 2):2308–2311. doi:10.1016/S0022-5347(17)31664-6.
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis. 2001;183(Supplement 1):S81–S83. doi:10.1086/318839.
   PubMedGoogle Scholar
• Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003;170(3):867–869. doi:10.1097/01.ju.0000075094.54767.6e.
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WJ, Balish E, Xing Y, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J Urol. 1997;157(6):2049–2052. doi:10.1016/S0022-5347(01)64671-8.
   PubMed Web of Science ®Google Scholar
• Nayir A, Emre S, Sirin A, Bulut A, Alpay H, Tanman F. The effects of vaccination with inactivated uropathogenic bacteria in recurrent urinary tract infections of children. Vaccine. 1995;13(11):987–990. doi:10.1016/0264-410x(95)00022-s.
   PubMed Web of Science ®Google Scholar
• Nestler S, Peschel C, Horstmann AH, Vahlensieck W, Fabry W, Neisius A. Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent symptomatic uncomplicated bacterial urinary tract infections. Int Urol Nephrol. 2023;55(1):9–16. doi:10.1007/s11255-022-03379-y.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, Silva-Abuin JM. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J. 2013;24(1):127–134. doi:10.1007/s00192-012-1853-5.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Gómez MF, Padilla-Fernández B, García-Cenador MB, Virseda-RodrÃguez ÃJ, MartÃn-GarcÃa I, Sánchez-Escudero A, Vicente-Arroyo MJ, Mirón-Canelo JA. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Front Cell Infect Microbiol. 2015;5:50. doi:10.3389/fcimb.2015.00050.
   PubMed Web of Science ®Google Scholar
• Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. BJU Int. 2018;121(2):289–292. doi:10.1111/bju.14067.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Gómez MF, Foley S, Nickel JC, García-Cenador M-B, Padilla-Fernández B-Y, González-Casado I, Martínez-Huélamo M, Yang B, Blick C, Ferreira F. et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid. 2022;1(4). doi:10.1056/EVIDoa2100018.
   PubMedGoogle Scholar
• Benito-Villalvilla C, Cirauqui C, Diez-Rivero CM, Casanovas M, Subiza JL, Palomares O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunol. 2017;10(4):924–935. doi:10.1038/mi.2016.112.
   PubMed Web of Science ®Google Scholar
• Liu B, Furevi A, Perepelov AV, Guo X, Cao H, Wang Q, Reeves PR, Knirel YA, Wang L, Widmalm G. et al. Structure and genetics of Escherichia coli O antigens. FEMS Microbiol Rev. 2020;44(6):655–683. doi:10.1093/femsre/fuz028.
   PubMed Web of Science ®Google Scholar
• Whitfield C. Structure and assembly of Escherichia coli capsules. EcoSal Plus. 2009;3(2). doi:10.1128/ecosalplus.4.7.3.
   PubMedGoogle Scholar
• Kaijser B, Jodal U, Hanson LÅ. Studies on antibody response and tolerance to E. coli K antigens in immunized rabbits and in children with urinary tract infection. Int Arch Allergy Immunol. 2009;44(2):260–273. doi:10.1159/000230935.
   Google Scholar
• Henriksen AZ, Maeland JA. Serum antibodies to outer membrane proteins of Escherichia coli in healthy persons and patients with bacteremia. J Clin Microbiol. 1987;25(11):2181–2188. doi:10.1128/jcm.25.11.2181-2188.1987.
   PubMed Web of Science ®Google Scholar
• Kaijser B, Ahlstedt S. Protective capacity of antibodies against Escherichia coli and K antigens. Infect Immun. 1977;17(2):286–289. doi:10.1128/iai.17.2.286-289.1977.
   PubMed Web of Science ®Google Scholar
• Kaijser B. Studies on the K antibody response in rabbits immunized with a pool of five different K antigen-containing Escherichia coli. Int Arch Allergy Appl Immunol. 1981;65(3):300–303. doi:10.1159/000232769.
   PubMedGoogle Scholar
• Straube E, Nimmich W, Broschewitz U, Naumann G, Hacker K. Effect of immunization with Escherichia coli K1 antigen on the course of experimental infection of the urinary tract of the rat. Zentralblatt für Bakteriologie, Mikrobiologie und Hygiene Series A: Med Microbiol, Infect Dis, Virol, Parasitol. 1987;265(3):408–419. doi:10.1016/S0176-6724(87)80260-2.
   PubMedGoogle Scholar
• Kaijser B, Larsson P, Schneerson R. Protection against acute, ascending pyelonephritis caused by E.Coli in rats using isolated capsular antigen conjugated to a carrier substance. Pediatr Res. 1980;14(8):980–980. doi:10.1203/00006450-198008000-00040.
   Web of Science ®Google Scholar
• Chorro L, Li Z, Chu L, Singh S, Gu J, Kim J-H, Dutta K, Pan R, Kodali S, Ndreu D. et al. Preclinical immunogenicity and efficacy of optimized O25b O-Antigen glycoconjugates to prevent MDR ST131 E. coli infections. Infect Immun. 2022;90(4):e00022–22. doi:10.1128/iai.00022-22.
   PubMed Web of Science ®Google Scholar
• Naini A, Bartetzko MP, Sanapala SR, Broecker F, Wirtz V, Lisboa MP, Parameswarappa SG, Knopp D, Przygodda J, Hakelberg M. et al. Semisynthetic glycoconjugate vaccine candidates against Escherichia coli O25B induce functional IgG antibodies in mice. JACS Au. 2022;2(9):2135–2151. doi:10.1021/jacsau.2c00401.
   PubMedGoogle Scholar
• Kowarik M, Wetter M, Haeuptle MA, Braun M, Steffen M, Kemmler S, Ravenscroft N, De Benedetto G, Zuppiger M, Sirena D. et al. The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconj J. 2021;38(4):421–435. doi:10.1007/s10719-021-09985-9.
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Cross AS, Sadoff JC, Wegmann A, Que JU, Fürer E. Safety and immunogenicity of Escherichia coli 018 O-Specific polysaccharide (O-PS)-toxin a and O-PS-cholera toxin conjugate vaccines in humans. Journal Of Infectious Diseases. 1991;163(5):1040–1045. doi:10.1093/infdis/163.5.1040.
   PubMed Web of Science ®Google Scholar
• Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ Jr. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis. 1994;170(4):834–840. doi:10.1093/infdis/170.4.834.
   PubMed Web of Science ®Google Scholar
• Cross AS, Opal SM, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattacharjee AK. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine. 2003;21(31):4576–4587. doi:10.1016/s0264-410x(03)00483-3.
   PubMed Web of Science ®Google Scholar
• Cross AS, Greenberg N, Billington M, Zhang L, DeFilippi C, May RC, Bajwa KK. Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis. Vaccine. 2015;33(48):6719–6726. doi:10.1016/j.vaccine.2015.10.072.
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen GPJM, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G. et al. Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models. Vaccine. 2016;34(35):4152–4160. doi:10.1016/j.vaccine.2016.06.067.
   PubMed Web of Science ®Google Scholar
• Inoue M, Ogawa T, Tamura H, Hagiwara Y, Saito Y, Abbanat D, van den Dobbelsteen G, Hermans P, Thoelen S, Poolman J. et al. Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants. Hum Vaccines Immunother. 2018;14(9):2150–2157. doi:10.1080/21645515.2018.1474316.
   PubMed Web of Science ®Google Scholar
• Huttner A, Hatz C, van den DG, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K. et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17(5):528–537. doi:10.1016/S1473-3099(17)30108-1.
   PubMed Web of Science ®Google Scholar
• Frenck RW, Ervin J, Chu L, Abbanat D, Spiessens B, Go O, Haazen W, van den Dobbelsteen G, Poolman J, Thoelen S. et al. Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. Lancet Infect Dis. 2019;19(6):631–640. doi:10.1016/S1473-3099(18)30803-X.
   PubMed Web of Science ®Google Scholar
• Fierro CA, Sarnecki M, Doua J, Spiessens B, Go O, Davies TA, van den Dobbelsteen G, Poolman J, Abbanat D, Haazen W. et al. Safety, reactogenicity, immunogenicity, and dose selection of 10-valent extraintestinal pathogenic Escherichia coli bioconjugate vaccine (VAC52416) in adults aged 60–85 years in a randomized, multicenter, interventional, first-in-human, phase 1/2a study. Open Forum Infect Dis. 2023;10(8):ofad417. doi:10.1093/ofid/ofad417.
   PubMed Web of Science ®Google Scholar
• Huttner A, Gambillara V. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli. Clin Microbiol Infect. 2018;24(10):1046–1050. doi:10.1016/j.cmi.2018.05.009.
   PubMed Web of Science ®Google Scholar
• Weerdenburg E, Davies T, Morrow B, Zomer AL, Hermans P, Go O, Spiessens B, van den Hoven T, van Geet G, Aitabi M. et al. Global distribution of O serotypes and antibiotic resistance in extraintestinal pathogenic Escherichia coli collected from the blood of patients with bacteremia across multiple surveillance studies. Clin Infect Dis. 2023;76(3):e1236–e1243. doi:10.1093/cid/ciac421.
   PubMed Web of Science ®Google Scholar
• Lindberg U, Hanson LA, Jodal U, Lidin-Janson G, Lincoln K, Olling S. Asymptomatic bacteriuria in schoolgirls. Acta Paediatr. 1975;64(3):432–436. doi:10.1111/j.1651-2227.1975.tb03860.x.
   Web of Science ®Google Scholar
• Blanco M, Blanco JE, Alonso MP, Blanco J. Virulence factors and O groups of Escherichia coli isolates from patients with acute pyelonephritis, cystitis and asymptomatic bacteriuria. Eur J Epidemiol. 1996;12(2):191–198. doi:10.1007/BF00145506.
   PubMed Web of Science ®Google Scholar
• Pokharel P, Dhakal S, Dozois CM. The diversity of Escherichia coli pathotypes and vaccination strategies against this versatile bacterial pathogen. Microorganisms. 2023;11(2):344. doi:10.3390/microorganisms11020344.
   PubMed Web of Science ®Google Scholar
• Lloyd AL, Rasko DA, Mobley HLT. Defining genomic islands and uropathogen-specific genes in uropathogenic Escherichia coli. J Bacteriol. 2007;189(9):3532–3546. doi:10.1128/JB.01744-06.
   PubMed Web of Science ®Google Scholar
• Moriel DG, Tan L, Goh KGK, Phan M-D, Ipe DS, Lo AW, Peters KM, Ulett GC, Beatson SA, Schembri MA. et al. A novel protective vaccine antigen from the core Escherichia coli genome. mSphere. 2016;1(6):e00326–16. doi:10.1128/mSphere.00326-16.
   PubMed Web of Science ®Google Scholar
• Soltan MA, Behairy MY, Abdelkader MS, Albogami S, Fayad E, Eid RA, Darwish KM, Elhady SS, Lotfy AM, Alaa Eldeen M. et al. In silico designing of an epitope-based vaccine against common E. coli pathotypes. Front Med. 2022;9:829467. doi:10.3389/fmed.2022.829467.
   Web of Science ®Google Scholar
• Clark JR, Maresso AM, Monack D. Comparative pathogenomics of Escherichia coli: Polyvalent vaccine target identification through virulome analysis. Infect Immun. 2021;89(8):e0011521. doi:10.1128/IAI.00115-21.
   PubMed Web of Science ®Google Scholar
• Xing Y, Clark JR, Chang JD, Chirman DM, Green S, Zulk JJ, Jelinski J, Patras KA, Maresso AW. Broad protective vaccination against systemic Escherichia coli with autotransporter antigens. PloS Pathog. 2023;19(2):e1011082. doi:10.1371/journal.ppat.1011082.
   PubMed Web of Science ®Google Scholar
• Cotugno N, Ruggiero A, Santilli V, Manno EC, Rocca S, Zicari S, Amodio D, Colucci M, Rossi P, Levy O. et al. OMIC technologies and vaccine development: from the identification of vulnerable individuals to the formulation of invulnerable vaccines. J Immunol Res. 2019;2019:1–10. doi:10.1155/2019/8732191.
   Web of Science ®Google Scholar
• Adamczyk-Poplawska M, Markowicz S, Jagusztyn-Krynicka EK. Proteomics for development of vaccine. J Proteomics. 2011;74(12):2596–2616. doi:10.1016/j.jprot.2011.01.019.
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A. et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449–W454. doi:10.1093/nar/gkaa379.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, Røder G, Peters B, Sette A, Lund O. et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLOS ONE. 2007;2(8):e796. doi:10.1371/journal.pone.0000796.
   PubMed Web of Science ®Google Scholar
• Fonseca AF, Antunes DA. CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases. Front Immunol. 2023;14:1142573. doi:10.3389/fimmu.2023.1142573.
   PubMed Web of Science ®Google Scholar
• Wieser A, Romann E, Magistro G, Hoffmann C, Nörenberg D, Weinert K, Schubert S. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun. 2010;78(8):3432–3442. doi:10.1128/iai.00174-10.
   PubMed Web of Science ®Google Scholar
• Hasanzadeh S, Habibi M, Shokrgozar MA, Ahangari Cohan R, Ahmadi K, Asadi Karam MR, Bouzari S. In silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic Escherichia coli. Sci Rep. 2020;10(1):16258. doi:10.1038/s41598-020-73179-w.
   PubMed Web of Science ®Google Scholar
• Wu XR, Sun TT, Medina JJ. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci. 1996;93(18):9630–9635. doi:10.1073/pnas.93.18.9630.
   PubMed Web of Science ®Google Scholar
• Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH. et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997;276(5312):607–611. doi:10.1126/science.276.5312.607.
   PubMed Web of Science ®Google Scholar
• Asadi Karam MR, Habibi M, Bouzari S. Use of flagellin and cholera toxin as adjuvants in intranasal vaccination of mice to enhance protective immune responses against uropathogenic Escherichia coli antigens. Biologicals. 2016;44(5):378–386. doi:10.1016/j.biologicals.2016.06.006.
   PubMed Web of Science ®Google Scholar
• Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice. Vaccine. 2013;31(8):1210–1216. doi:10.1016/j.vaccine.2012.12.059.
   PubMed Web of Science ®Google Scholar
• Karam MRA, Oloomi M, Mahdavi M, Habibi M, Bouzari S. Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic Escherichia coli. Mol Immunol. 2013;54(1):32–39. doi:10.1016/j.molimm.2012.11.002.
   PubMed Web of Science ®Google Scholar
• Savar NS, Jahanian-Najafabadi A, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. J Biotechnol. 2014;175:31–37. doi:10.1016/j.jbiotec.2014.01.037.
   PubMed Web of Science ®Google Scholar
• Langermann S, Möllby R, Burlein JE, Palaszynski S, Auguste C, DeFusco A, Strouse R, Schenerman M, Hultgren S, Pinkner J. et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis. 2000;181(2):774–778. doi:10.1086/315258.
   PubMed Web of Science ®Google Scholar
• Brumbaugh AR, Mobley HLT. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(6):663–676. doi:10.1586/erv.12.36.
   PubMed Web of Science ®Google Scholar
• Hagan EC, Lloyd AL, Rasko DA, Faerber GJ, Mobley HLT, Cheung A. Escherichia coli global gene expression in urine from women with urinary tract infection. PloS Pathog. 2010;6(11):e1001187. doi:10.1371/journal.ppat.1001187.
   PubMed Web of Science ®Google Scholar
• Lim JK, Gunther NW, Zhao H, Johnson DE, Keay SK, Mobley HLT. In vivo Phase Variation of Escherichia coli type 1 fimbrial genes in women with urinary tract infection. Infect Immun. 1998;66(7):3303–3310. doi:10.1128/iai.66.7.3303-3310.1998.
   PubMed Web of Science ®Google Scholar
• Eisenstein BI. Phase variation of type 1 fimbriae in Escherichia coli is under transcriptional control. Science. 1981;214(4518):337–339. doi:10.1126/science.6116279.
   PubMed Web of Science ®Google Scholar
• Nowicki B, Rhen M, VäVäIsänenänen-Rhen V, Pere A, Korhonen TK. Immunofluorescence study of fimbrial phase variation in Escherichia coli KS71. J Bacteriol. 1984;160(2):691–695. doi:10.1128/jb.160.2.691-695.1984.
   PubMed Web of Science ®Google Scholar
• Tchesnokova V, Aprikian P, Kisiela D, Gowey S, Korotkova N, Thomas W, Sokurenko E. Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli. Infect Immun. 2011;79(10):3895–3904. doi:10.1128/iai.05169-11.
   PubMed Web of Science ®Google Scholar
• Eldridge GR, Hughey H, Rosenberger L, Martin SM, Shapiro AM, D’Antonio E, Krejci KG, Shore N, Peterson J, Lukes AS. et al. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study. Hum Vaccin Immunother. 2021;17(5):1262–1270. doi:10.1080/21645515.2020.1834807.
   PubMed Web of Science ®Google Scholar
• Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VAM, Torricelli G, Cartocci E. et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA. 2010;107(20):9072–9077. doi:10.1073/pnas.0915077107.
   PubMed Web of Science ®Google Scholar
• Goluszko P, Goluszko E, Nowicki B, Nowicki S, Popov V, Wang HQ. Vaccination with purified dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing dr adhesin. Infect Immun. 2005;73(1):627–631. doi:10.1128/IAI.73.1.627-631.2005.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kaack MB, Baskin G, Chapman MR, Hunstad DA, Pinkner JS, Hultgren SJ. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol. 2004;171(4):1682–1685. doi:10.1097/01.ju.0000116123.05160.43.
   PubMed Web of Science ®Google Scholar
• Nesta B, Spraggon G, Alteri C, Gomes Moriel D, Rosini R, Veggi D, Smith S, Bertoldi I, Pastorello I, Ferlenghi I. et al. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. mBio. 2012;3(2): doi:10.1128/mbio.00010-12.
   PubMed Web of Science ®Google Scholar
• Reigstad CS, Hultgren SJ, Gordon JI. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J Biol Chem. 2007;282(29):21259–21267. doi:10.1074/jbc.M611502200.
   PubMed Web of Science ®Google Scholar
• Snyder JA, Haugen BJ, Buckles EL, Lockatell CV, Johnson DE, Donnenberg MS, Welch RA, Mobley HLT. Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect Immun. 2004;72(11):6373–6381. doi:10.1128/iai.72.11.6373-6381.2004.
   PubMed Web of Science ®Google Scholar
• Hagan EC, Mobley HLT. Haem acquisition is facilitated by a novel receptor Hma and required by uropathogenic Escherichia coli for kidney infection. Mol Microbiol. 2009;71(1):79–91. doi:10.1111/j.1365-2958.2008.06509.x.
   PubMed Web of Science ®Google Scholar
• Bauckman KA, Mysorekar IU. Ferritinophagy drives uropathogenic Escherichia coli persistence in bladder epithelial cells. Autophagy. 2016;12(5):850–863. doi:10.1080/15548627.2016.1160176.
   PubMed Web of Science ®Google Scholar
• Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HLT, Seifert HS. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLOS Pathog. 2009;5(9):e1000586. doi:10.1371/journal.ppat.1000586.
   PubMed Web of Science ®Google Scholar
• Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun. 2007;75(4):1916–1925. doi:10.1128/IAI.01269-06.
   PubMed Web of Science ®Google Scholar
• Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. The siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun. 2003;71(12):7164–7169. doi:10.1128/IAI.71.12.7164-7169.2003.
   PubMed Web of Science ®Google Scholar
• Brumbaugh AR, Smith SN, Mobley HLT, Payne SM. Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect Immun. 2013;81(9):3309–3316. doi:10.1128/iai.00470-13.
   PubMed Web of Science ®Google Scholar
• Habibi M, Asadi Karam MR, Bouzari S. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection. Microb Pathog. 2017;110:477–483. doi:10.1016/j.micpath.2017.07.037.
   PubMed Web of Science ®Google Scholar
• Wieser A, Magistro G, Nörenberg D, Hoffmann C, Schubert S. First multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli delivered by a bacterial type-3 secretion system (T3SS). Int J Med Microbiol. 2012;302(1):10–18. doi:10.1016/j.ijmm.2011.09.012.
   PubMed Web of Science ®Google Scholar
• Mike LA, Smith SN, Sumner CA, Eaton KA, Mobley HLT. Siderophore vaccine conjugates protect against uropathogenic Escherichia coli urinary tract infection. Proc Natl Acad Sci. 2016;113(47):13468–13473. doi:10.1073/pnas.1606324113.
   PubMed Web of Science ®Google Scholar
• Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol. 2008;85(1):11–19. doi:10.1016/j.yexmp.2008.03.007.
   PubMed Web of Science ®Google Scholar
• Smith MA, Weingarten RA, Russo LM, Ventura CL, O’Brien AD, Payne SM. Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli. Infect Immun. 2015;83(4):1661–1673. doi:10.1128/IAI.02848-14.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2): doi:10.1128/cmr.00084-18.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509–517. doi:10.1038/ni.2039.
   PubMed Web of Science ®Google Scholar
• Siegrist CA. 2 - vaccine immunology. In: Plotkin S, Orenstein W, Offit P, and Edwards K. editors. Plotkin’s Vaccines. 7th ed. Philadelphia, PA: Elsevier. 2018. p. 16–34.e7. doi:10.1016/B978-0-323-35761-6.00002-X.
   Google Scholar
• Plotkin SA, Gilbert P. 3 - correlates of protection. In: Plotkin S, Orenstein W, Offit P, and Edwards K. editors. Plotkin’s Vaccines. 7th ed. Philadelphia, PA: Elsevier. 2018. p. 35–40.e4. doi:10.1016/B978-0-323-35761-6.00003-1.
   Google Scholar
• Diphtheria T. And pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep. 1991;40(RR–10):1–28.
   Google Scholar
• Dijkman K, Sombroek CC, Vervenne RAW, Hofman SO, Boot C, Remarque EJ, Kocken CHM, Ottenhoff THM, Kondova I, Khayum MA. et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat Med. 2019;25(2):255–262. doi:10.1038/s41591-018-0319-9.
   PubMed Web of Science ®Google Scholar
• Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, Maiello P, Rutledge T, Marino S, Fortune SM. et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLOS Pathog. 2015;11(1):e1004603. doi:10.1371/journal.ppat.1004603.
   PubMed Web of Science ®Google Scholar
• Thumbikat P, Waltenbaugh C, Schaeffer AJ, Klumpp DJ. Antigen-specific responses accelerate bacterial clearance in the Bladder1. J Immunol. 2006;176(5):3080–3086. doi:10.4049/jimmunol.176.5.3080.
   PubMed Web of Science ®Google Scholar
• Mulvey MA, Schilling JD, Hultgren SJ, O’Brien AD. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69(7):4572–4579. doi:10.1128/iai.69.7.4572-4579.2001.
   PubMed Web of Science ®Google Scholar
• Lukens JR, Anand PK. Adapt(ed) to repair — TH2 immune responses in the bladder promote recurrent infections. Nat Immunol. 2020;21(6):597–599. doi:10.1038/s41590-020-0689-2.
   PubMed Web of Science ®Google Scholar
• Sharma K, Thacker VV, Dhar N, Clapés Cabrer M, Dubois A, Signorino-Gelo F, Mullenders J, Knott GW, Clevers H, McKinney JD. Early invasion of the bladder wall by solitary bacteria protects UPEC from antibiotics and neutrophil swarms in an organoid model. Cell Rep. 2021;36(3):109351. doi:10.1016/j.celrep.2021.109351.
   PubMed Web of Science ®Google Scholar
• Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA, Beloin C. Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS One. 2014;9(3):e93327. doi:10.1371/journal.pone.0093327.
   PubMed Web of Science ®Google Scholar
• Wu J, Hayes BW, Phoenix C, Macias GS, Miao Y, Choi HW, Hughes FM, Todd Purves J, Lee Reinhardt R, Abraham SN. et al. A highly polarized TH2 bladder response to infection promotes epithelial repair at the expense of preventing new infections. Nat Immunol. 2020;21(6):671–683. doi:10.1038/s41590-020-0688-3.
   PubMed Web of Science ®Google Scholar
• Wu J, Bao C, Reinhardt RL, Abraham SN. Local induction of bladder Th1 responses to combat urinary tract infections. Proc Natl Acad Sci. 2021;118(10):e2026461118. doi:10.1073/pnas.2026461118.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010;33(4):451–463. doi:10.1016/j.immuni.2010.10.008.
   PubMed Web of Science ®Google Scholar
• Mora-Bau G, Platt AM, van RN, Randolph GJ, Albert ML, Ingersoll MA, Gause WC. Macrophages subvert adaptive immunity to urinary tract infection. PloS Pathog. 2015;11(7):e1005044. doi:10.1371/journal.ppat.1005044.
   PubMed Web of Science ®Google Scholar
• Rousseau M, Lacerda Mariano L, Canton T, Ingersoll MA. Tissue-resident memory T cells mediate mucosal immunity to recurrent urinary tract infection. Sci Immunol. 2023;8(83):eabn4332. doi:10.1126/sciimmunol.abn4332.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Ward RW. Mucosal vaccines — fortifying the frontiers. Nat Rev Immunol. 2022;22(4):236–250. doi:10.1038/s41577-021-00583-2.
   PubMed Web of Science ®Google Scholar
• Marinova S, Nenkov P, Markova R, Nikolaeva S, Kostadinova R, Mitov I, Vretenarska M. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections. Int J Immunopathol Pharmacol. 2005;18(3):457–473. doi:10.1177/039463200501800306.
   PubMed Web of Science ®Google Scholar
• Forsyth VS, Himpsl SD, Smith SN, Sarkissian CA, Mike LA, Stocki JA, Sintsova A, Alteri CJ, Mobley HLT. et al. Optimization of an experimental vaccine to prevent Escherichia coli urinary tract infection. mBio. 2020;11(2): doi:10.1128/mbio.00555-20.
   PubMed Web of Science ®Google Scholar
• Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A. et al. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2020;20(2):208–219. doi:10.1016/S1473-3099(19)30571-7.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm A-M. et al. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine. 2013;31(20):2457–2464. doi:10.1016/j.vaccine.2013.03.027.
   PubMed Web of Science ®Google Scholar
• Kennedy KJ, Roberts JL, Collignon PJ. Escherichia coli bacteraemia in Canberra: incidence and clinical features. Med J Aust. 2008;188(4):209–213. doi:10.5694/j.1326-5377.2008.tb01586.x.
   PubMed Web of Science ®Google Scholar
• Baudron CR, Panhard X, Clermont O, MENTRÉ F, Fantin B, Denamur E, Lefort A. Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome. Epidemiol Infect. 2014;142(12):2672–2683. doi:10.1017/S0950268814000211.
   PubMed Web of Science ®Google Scholar
• Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018;219(1):40–51. doi:10.1016/j.ajog.2017.12.231.
   PubMed Web of Science ®Google Scholar
• Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging Health. 2013;9(5):519–528. doi:10.2217/ahe.13.38.
   Google Scholar
• Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16(1):25. doi:10.1186/s12979-019-0164-9.
   PubMed Web of Science ®Google Scholar
• Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114(1):37–43. doi:10.1111/j.1365-2567.2004.02006.x.
   PubMed Web of Science ®Google Scholar
• Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, Pellicanò M, Wu Y-C, Colonna Romano G. B cells and immunosenescence: a focus on IgG+IgD−CD27− (DN) B cells in aged humans. Ageing Res Rev. 2011;10(2):274–284. doi:10.1016/j.arr.2010.12.002.
   PubMed Web of Science ®Google Scholar
• Listì F, Candore G, Modica MA, Russo M, Lorenzo GD, Esposito‐Pellitteri M, Colonna‐Romano G, Aquino A, Bulati M, Lio D. et al. A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci. 2006;1089(1):487–495. doi:10.1196/annals.1386.013.
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–1169. doi:10.1016/j.vaccine.2005.08.105.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng N-Y, Nishtala M, Wrammert J, Smith K, James JA. et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011;121(8):3109–3119. doi:10.1172/JCI57834.
   PubMed Web of Science ®Google Scholar
• Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol. 2004;172(6):3437–3446. doi:10.4049/jimmunol.172.6.3437.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Harpaz R, Luo Y, Hales, CM, Sy, LS, Tartof, SY, Bialek, S, Hechter, RC, Jacobsen, SJ. et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872–1875. doi:10.1093/infdis/jiw047.
   PubMed Web of Science ®Google Scholar
• Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respi Viruses. 2021;15(6):813–823. doi:10.1111/irv.12871.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S. et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018;14(6):1370–1377. doi:10.1080/21645515.2018.1442162.
   PubMed Web of Science ®Google Scholar
• Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589–1603. doi:10.1016/j.cell.2021.02.030.
   PubMed Web of Science ®Google Scholar
• Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging Concepts and technologies in vaccine development. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.583077.
   PubMed Web of Science ®Google Scholar
• Tam HH, Melo MB, Kang M, Pelet JM, Ruda VM, Foley MH, Hu JK, Kumari S, Crampton J, Baldeon AD. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci. 2016;113(43):E6639–E6648. doi:10.1073/pnas.1606050113.
   PubMed Web of Science ®Google Scholar
• Cirelli KM, Crotty S. Germinal center enhancement by extended antigen availability. Curr Opin Immunol. 2017;47:64–69. doi:10.1016/j.coi.2017.06.008.
   PubMed Web of Science ®Google Scholar
• Cirelli KM, Carnathan DG, Nogal B, Martin JT, Rodriguez OL, Upadhyay AA, Enemuo CA, Gebru EH, Choe Y, Viviano F. et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell. 2019;177(5):1153–1171.e28. doi:10.1016/j.cell.2019.04.012.
   PubMed Web of Science ®Google Scholar
• Byrd W, de Lorimier A, Zheng ZR, Cassels FJ. Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens. Adv Drug Deliv Rev. 2005;57(9):1362–1380. doi:10.1016/j.addr.2005.01.014.
   PubMed Web of Science ®Google Scholar
• Rezaei M, Esmaeili F, Reza Asadi Karam M, Ehsani P, Abbasnezhad Farsangi Z, Bouzari S. In silico design and in vivo evaluation of two multi-epitope vaccines containing build-in adjuvant with chitosan nanoparticles against uropathogenic Escherichia coli. Int Immunopharmacol. 2023;117:109999. doi:10.1016/j.intimp.2023.109999.
   PubMed Web of Science ®Google Scholar
• Gu H, Liao Y, Zhang J, Wang Y, Liu Z, Cheng P, Wang X, Zou Q, Gu J. Rational design and evaluation of an artificial Escherichia coli K1 protein vaccine candidate based on the structure of OmpA. Front Cell Infect Microbiol. 2018 [accessed 2023 Oct 16]. 8. https://www.frontiersin.org/articles/10.3389/fcimb.2018.00172.
   Web of Science ®Google Scholar
• Zhang J, Sun H, Gao C, Wang Y, Cheng X, Yang Y, Gou Q, Lei L, Chen Y, Wang X. et al. Development of a chitosan‐modified PLGA nanoparticle vaccine for protection against Escherichia coli K1 caused meningitis in mice. J Nanobiotechnology. 2021;19(1):69. doi:10.1186/s12951-021-00812-9.
   PubMed Web of Science ®Google Scholar
• Luzuriaga MA, Herbert FC, Brohlin OR, Gadhvi J, Howlett T, Shahrivarkevishahi A, Wijesundara YH, Venkitapathi S, Veera K, Ehrman R. et al. Metal–organic framework encapsulated whole-cell vaccines enhance humoral immunity against bacterial infection. Acs Nano. 2021;15(11):17426–17438. doi:10.1021/acsnano.1c03092.
   PubMed Web of Science ®Google Scholar
• Kelly SH, Wu Y, Varadhan AK, Curvino EJ, Chong AS, Collier JH. Enabling sublingual peptide immunization with molecular self-assemblies. Biomaterials. 2020;241:119903. doi:10.1016/j.biomaterials.2020.119903.
   PubMed Web of Science ®Google Scholar
• Kelly SH, Votaw NL, Cossette BJ, Wu Y, Shetty S, Shores LS, Issah LA, Collier JH. A sublingual nanofiber vaccine to prevent urinary tract infections. Sci Adv. 2022;8(47). doi:10.1126/sciadv.abq4120.
   Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–788. doi:10.1038/nrg2432.
   PubMed Web of Science ®Google Scholar
• Imani Fooladi AA, Bagherpour G, Khoramabadi N, Fallah Mehrabadi J, Mahdavi M, Halabian R, Amin M, Izadi Mobarakeh J, Einollahi B. Cellular immunity survey against urinary tract infection using pVAX/fimH cassette with mammalian and wild type codon usage as a DNA vaccine. Clin Exp Vaccine Res. 2014;3(2):185–193. doi:10.7774/cevr.2014.3.2.185.
   PubMedGoogle Scholar
• Bakhtiari R, Ahmadian S, Fallah Mehrabadi J. Rising cellular immune response after injection of pVax/iutA: A genetic DNA cassette as candidate vaccine against urinary tract infection. Iran J Public Health. 2016;45(7):890–896.
   PubMed Web of Science ®Google Scholar
• Denamur E, Clermont O, Bonacorsi S, Gordon D. The population genetics of pathogenic Escherichia coli. Nat Rev Microbiol. 2021;19(1):37–54. doi:10.1038/s41579-020-0416-x.
   PubMed Web of Science ®Google Scholar
• Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem. 2006;75(1):39–68. doi:10.1146/annurev.biochem.75.103004.142545.
   PubMedGoogle Scholar
• Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bingen E, Elion J, Denamur E. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun. 1999;67(2):546–553. doi:10.1128/IAI.67.2.546-553.1999.
   PubMed Web of Science ®Google Scholar
• Escobar-Páramo P, Clermont O, Blanc-Potard AB, Bui H, Le Bouguénec C, Denamur E. A specific genetic background is required for acquisition and expression of virulence factors in Escherichia coli. Mol Biol Evol. 2004;21(6):1085–1094. doi:10.1093/molbev/msh118.
   PubMed Web of Science ®Google Scholar
• Mehat JW, van Vliet AHM, La Ragione RM. The avian pathogenic Escherichia coli (APEC) pathotype is comprised of multiple distinct, independent genotypes. Avian Pathol. 2021;50(5):402–416. doi:10.1080/03079457.2021.1915960.
   PubMed Web of Science ®Google Scholar
• Eichhorn I, Heidemanns K, Semmler T, Kinnemann B, Mellmann A, Harmsen D, Anjum MF, Schmidt H, Fruth A, Valentin-Weigand P. et al. Highly virulent non-O157 Enterohemorrhagic Escherichia coli (EHEC) serotypes reflect similar phylogenetic lineages, providing new insights into the evolution of EHEC. Appl Environ Microbiol. 2015;81(20):7041–7047. doi:10.1128/AEM.01921-15.
   PubMed Web of Science ®Google Scholar
• Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8(3):207–217. doi:10.1038/nrmicro2298.
   PubMed Web of Science ®Google Scholar
• Clermont O, Dixit OVA, Vangchhia B, Condamine B, Dion S, Bridier‐Nahmias A, Denamur E, Gordon D. Characterization and rapid identification of phylogroup G in Escherichia coli, a lineage with high virulence and antibiotic resistance potential. Environ Microbiol. 2019;21(8):3107–3117. doi:10.1111/1462-2920.14713.
   PubMed Web of Science ®Google Scholar
• Vangchhia B, Abraham S, Bell JM, Collignon P, Gibson JS, Ingram PR, Johnson JR, Kennedy K, Trott DJ, Turnidge JD. et al. Phylogenetic diversity, antimicrobial susceptibility and virulence characteristics of phylogroup F Escherichia coli in Australia. Microbiol. 2016;162(11):1904–1912. doi:10.1099/mic.0.000367.
   PubMed Web of Science ®Google Scholar
• Escobar-Páramo P, Grenet K, Le Menac’h A, Rode L, Salgado E, Amorin C, Gouriou S, Picard B, Rahimy MC, Andremont A. et al. Large-scale population structure of human commensal Escherichia coli isolates. Appl Environ Microbiol. 2004;70(9):5698–5700. doi:10.1128/AEM.70.9.5698-5700.2004.
   PubMed Web of Science ®Google Scholar
• Duriez P, Clermont O, Bonacorsi S, Bingen E, Chaventré A, Elion J, Picard B, Denamur E. Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations. Microbiol. 2001;147(6):1671–1676. doi:10.1099/00221287-147-6-1671.
   PubMedGoogle Scholar
• Gomez A, Petrzelkova KJ, Burns MB, Yeoman C, Amato K, Vlckova K, Modry D, Todd A, Jost Robinson C, Remis M. et al. Gut microbiome of coexisting BaAka pygmies and bantu reflects gradients of traditional subsistence patterns. Cell Rep. 2016;14(9):2142–2153. doi:10.1016/j.celrep.2016.02.013.
   PubMed Web of Science ®Google Scholar
• Lescat M, Clermont O, Woerther PL, Glodt J, Dion S, Skurnik D, Djossou F, Dupont C, Perroz G, Picard B. et al. Commensal Escherichia coli strains in Guiana reveal a high genetic diversity with host-dependant population structure. Environ Microbiol Rep. 2013;5(1):49–57. doi:10.1111/j.1758-2229.2012.00374.x.
   PubMed Web of Science ®Google Scholar
• Touchon M, Perrin A, de SJ, Vangchhia B, Burn S, O’Brien CL, Denamur E, Gordon D, Rocha EP. Phylogenetic background and habitat drive the genetic diversification of Escherichia coli. PLOS Genet. 2020;16(6):e1008866. doi:10.1371/journal.pgen.1008866.
   PubMed Web of Science ®Google Scholar
• Arimizu Y, Kirino Y, Sato MP, Uno K, Sato T, Gotoh Y, Auvray F, Brugere H, Oswald E, Mainil JG. et al. Large-scale genome analysis of bovine commensal Escherichia coli reveals that bovine-adapted E. coli lineages are serving as evolutionary sources of the emergence of human intestinal pathogenic strains. Genome Res. 2019;29(9):1495–1505. doi:10.1101/gr.249268.119.
   PubMed Web of Science ®Google Scholar
• Massot M, Daubié AS, Clermont O, Jauréguy F, Couffignal C, Dahbi G, Mora A, Blanco J, Branger C, Mentré F. et al. Phylogenetic, virulence and antibiotic resistance characteristics of commensal strain populations of Escherichia coli from community subjects in the Paris area in 2010 and evolution over 30 years. Microbiol. 2016;162(4):642–650. doi:10.1099/mic.0.000242.
   PubMedGoogle Scholar
• Mercat M, Clermont O, Massot M, Ruppe E, de Garine-Wichatitsky M, Miguel E, Valls Fox H, Cornelis D, Andremont A, Denamur E. et al. Escherichia coli population structure and antibiotic resistance at a buffalo/cattle interface in Southern Africa. Appl Environ Microbiol. 2015;82(5):1459–1467. doi:10.1128/AEM.03771-15.
   PubMed Web of Science ®Google Scholar
• Coura FM, de A Diniz S, Silva MX, Mussi JMS, Barbosa SM, Lage AP, Heinemann MB. Phylogenetic group determination of Escherichia coli Isolated from animals samples. The Scientific World Journal. 2015;2015:1–4. doi:10.1155/2015/258424.
   Google Scholar
• Clermont O, Condamine B, Dion S, Gordon DM, Denamur E. The E phylogroup of Escherichia coli is highly diverse and mimics the whole E. coli species population structure. Environ Microbiol. 2021;23(11):7139–7151. doi:10.1111/1462-2920.15742.
   PubMed Web of Science ®Google Scholar